BAJAJ BROKING

Notification close image
No new Notification messages
card image
Seshaasai Technologies Ltd IPO
Apply for the Seshaasai Technologies Ltd IPO through UPI in Just minutes
delete image
card image
Start your SIP with just ₹100
Choose from 4,000+ Mutual Funds on Bajaj Broking
delete image
card image
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
delete image
card image
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
delete image
card image
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.
delete image

28888

544319

SENORES

img img img img
No Data Available

SENORES PHARMACEUTICALS L performance

Today’s low

Today’s high

₹ 810.15 ₹ 825.90
₹ 816.40

52 week low

52 week high

₹ 435.25 ₹ 848.50
₹ 816.40

Open Price

₹ 825.00

Prev. Close

₹ 815.25

Volume (Shares)

1374406.00

Total traded value

₹ 11220.65

Upper Circuit

₹ 978.30

Lower Circuit

₹ 652.20

info

SENORES PHARMACEUTICALS L Share Price Update

As of the latest trading session, SENORES PHARMACEUTICALS L share price is currently at ₹ 813.85, which is down by ₹ -1.40 from its previous closing. Today, the stock has fluctuated between ₹ 810.15 and ₹ 825.90. Over the past year, SENORES PHARMACEUTICALS L has achieved a return of 41.11 %. In the last month alone, the return has been 1.22 %. Read More...

Investment Returns

Over 1 Month [-]% Over 3 Months [-]% Over 6 Months [-]% Over 1 Year [-]%
demotext Smart Investing Starts here ! Trade Smart with Fast Execution & Zero Account Opening Fees Invest Now

SENORES PHARMACEUTICALS L fundamentals


  • Market cap (Cr)

    3,759.80

  • P/E Ratio (TTM)

    296.06

  • Beta

    1.48

  • Book Value / share

    155.05

  • Return on equity

    0.84%

  • EPS (TTM)

    2.65

  • Dividend yield

    0.00%

  • Net profit/quarter (Cr)

    6.43

info icon alternate text
  • Market cap (Cr)

    3,765.60

  • P/E Ratio (TTM)

    307.75

  • Beta

    1.38

  • Book Value / share

    155.05

  • Return on equity

    0.84%

  • EPS (TTM)

    2.65

  • Dividend yield

    0.00%

  • Net profit/quarter (Cr)

    6.43

info icon alternate text

SENORES PHARMACEUTICALS L Financials

  • Key Results

  • Key Ratios

  • Balance sheet

  • Cash Flow

  • Competition

info-icon

Revenue

Net income

Particulars SEP 2025 (Values in Cr)
Revenue 20.92
Operating Expense 39.04
Net Profit 6.43
Net Profit Margin (%) 30.73
Earnings Per Share (EPS) 1.40
EBITDA 12.88
Effective Tax Rate (%) 15.94
Particulars JUN 2025 (Values in Cr)
Revenue 15.49
Operating Expense 24.62
Net Profit 2.70
Net Profit Margin (%) 17.43
Earnings Per Share (EPS) 0.59
EBITDA 7.22
Effective Tax Rate (%) 24.79
Particulars MAR 2025 (Values in Cr)
Revenue 11.86
Operating Expense 18.22
Net Profit 2.01
Net Profit Margin (%) 16.94
Earnings Per Share (EPS) 0.39
EBITDA 6.51
Effective Tax Rate (%) 30.44
Particulars DEC 2024 (Values in Cr)
Revenue 9.59
Operating Expense 15.46
Net Profit 1.07
Net Profit Margin (%) 11.15
Earnings Per Share (EPS) 0.32
EBITDA 4.77
Effective Tax Rate (%) 18.93
Particulars SEP 2024 (Values in Cr)
Revenue 9.63
Operating Expense 12.18
Net Profit 0.30
Net Profit Margin (%) 3.11
Earnings Per Share (EPS) 0.09
EBITDA 1.75
Effective Tax Rate (%) 44.44
Particulars MAR 2025 (Values in Cr)
Revenue 38.54
Operating Expense 55.42
Net Profit 3.69
Net Profit Margin (%) 9.57
Earnings Per Share (EPS) 1.02
EBITDA 14.70
Effective Tax Rate (%) 27.78
Particulars MAR 2024 (Values in Cr)
Revenue 34.01
Operating Expense 38.83
Net Profit 0.81
Net Profit Margin (%) 2.38
Earnings Per Share (EPS) 0.35
EBITDA 6.78
Effective Tax Rate (%) 60.09
Particulars MAR 2023 (Values in Cr)
Revenue 12.38
Operating Expense 17.23
Net Profit 1.20
Net Profit Margin (%) 9.69
Earnings Per Share (EPS) 1.26
EBITDA 5.01
Effective Tax Rate (%) 38.14
Particulars MAR 2022 (Values in Cr)
Revenue 15.85
Operating Expense 15.98
Net Profit 0.29
Net Profit Margin (%) 1.82
Earnings Per Share (EPS) 0.33
EBITDA 1.97
Effective Tax Rate (%) 67.77
Particulars MAR 2021 (Values in Cr)
Revenue 7.91
Operating Expense 7.66
Net Profit 0.84
Net Profit Margin (%) 10.61
Earnings Per Share (EPS) 2.20
EBITDA 1.17
Effective Tax Rate (%) -109.99
Particulars MAR 2025 (Values in Cr)
Book Value / Share 170.72
ROE % 11.78
ROCE % 11.75
Total Debt to Total Equity 0.58
EBITDA Margin 27.36
Particulars MAR 2024 (Values in Cr)
Book Value / Share 66.95
ROE % 26.19
ROCE % 12.04
Total Debt to Total Equity 1.28
EBITDA Margin 20.70
Particulars MAR 2023 (Values in Cr)
Book Value / Share 46.36
ROE % 20.54
ROCE % 18.24
Total Debt to Total Equity 0.94
EBITDA Margin 46.29
Particulars MAR 2022 (Values in Cr)
Book Value / Share 41.86
ROE % 2.71
ROCE % 3.33
Total Debt to Total Equity 0.40
EBITDA Margin 17.08
Particulars MAR 2025 (Values in Cr)
Book Value / Share 153.74
ROE % 0.84
ROCE % 2.15
Total Debt to Total Equity 0.23
EBITDA Margin 38.17
Particulars MAR 2024 (Values in Cr)
Book Value / Share 55.10
ROE % 0.78
ROCE % 2.56
Total Debt to Total Equity 0.78
EBITDA Margin 19.94
Particulars MAR 2023 (Values in Cr)
Book Value / Share 39.66
ROE % 3.30
ROCE % 5.44
Total Debt to Total Equity 1.04
EBITDA Margin 40.47
Particulars MAR 2022 (Values in Cr)
Book Value / Share 38.54
ROE % 3.15
ROCE % 4.51
Total Debt to Total Equity 0.43
EBITDA Margin 15.51
Particulars MAR 2021 (Values in Cr)
Book Value / Share 24.91
ROE % 8.87
ROCE % 4.55
Total Debt to Total Equity 0.39
EBITDA Margin 14.79
Particulars MAR 2025 (Values in Cr)
Cash & Short Term Investments 385.50
Total Assets 1226.86
Total Liabilities 1226.86
Total Equity 812.24
Share Outstanding 46053588
Price to Book Ratio 3.73
Return on Assets (%) 4.77
Return on Capital (%) 5.24
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 13.06
Total Assets 621.88
Total Liabilities 621.88
Total Equity 231.71
Share Outstanding 30504615
Price to Book Ratio 0.00
Return on Assets (%) 5.05
Return on Capital (%) 6.55
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 0.10
Total Assets 131.05
Total Liabilities 131.05
Total Equity 45.49
Share Outstanding 9815000
Price to Book Ratio 0.00
Return on Assets (%) 6.43
Return on Capital (%) 7.94
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 3.21
Total Assets 59.15
Total Liabilities 59.15
Total Equity 36.59
Share Outstanding 9815000
Price to Book Ratio 0.00
Return on Assets (%) 1.67
Return on Capital (%) 1.95
Particulars MAR 2025 (Values in Cr)
Cash & Short Term Investments 359.72
Total Assets 834.09
Total Liabilities 834.09
Total Equity 707.97
Share Outstanding 46053588
Price to Book Ratio 3.73
Return on Assets (%) 0.44
Return on Capital (%) 0.46
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 10.45
Total Assets 285.86
Total Liabilities 285.86
Total Equity 168.12
Share Outstanding 30504615
Price to Book Ratio 0.00
Return on Assets (%) 0.28
Return on Capital (%) 0.31
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 0.09
Total Assets 111.71
Total Liabilities 111.71
Total Equity 38.92
Share Outstanding 9815000
Price to Book Ratio 0.00
Return on Assets (%) 1.07
Return on Capital (%) 1.21
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 1.40
Total Assets 55.16
Total Liabilities 55.16
Total Equity 33.69
Share Outstanding 7133000
Price to Book Ratio 0.00
Return on Assets (%) 1.23
Return on Capital (%) 1.42
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 1.64
Total Assets 14.95
Total Liabilities 14.95
Total Equity 9.46
Share Outstanding 3800000
Price to Book Ratio 0.00
Return on Assets (%) 5.58
Return on Capital (%) 6.35
Particulars MAR 2025 (Values in Cr)
Net Income 70.57
Cash from Operations -36.75
Cash from Investing -429.48
Cash from Financing 573.13
Net change in Cash 97.73
Free Cash Flow 120.77
Particulars MAR 2024 (Values in Cr)
Net Income 24.94
Cash from Operations -23.22
Cash from Investing -54.23
Cash from Financing 86.98
Net change in Cash 7.05
Free Cash Flow 28.61
Particulars MAR 2023 (Values in Cr)
Net Income 12.43
Cash from Operations 0.37
Cash from Investing -48.28
Cash from Financing 46.25
Net change in Cash -3.11
Free Cash Flow 47.65
Particulars MAR 2022 (Values in Cr)
Net Income 1.14
Cash from Operations -10.30
Cash from Investing -24.44
Cash from Financing 36.46
Net change in Cash 1.57
Free Cash Flow 0.37
Particulars MAR 2025 (Values in Cr)
Net Income 5.11
Cash from Operations -18.95
Cash from Investing -162.94
Cash from Financing 532.62
Net change in Cash 349.28
Free Cash Flow 30.16
Particulars MAR 2024 (Values in Cr)
Net Income 2.03
Cash from Operations -18.07
Cash from Investing -57.07
Cash from Financing 86.68
Net change in Cash 10.35
Free Cash Flow 1.19
Particulars MAR 2023 (Values in Cr)
Net Income 1.94
Cash from Operations -39.80
Cash from Investing -5.22
Cash from Financing 47.07
Net change in Cash -1.56
Free Cash Flow -31.42
Particulars MAR 2022 (Values in Cr)
Net Income 0.83
Cash from Operations -23.91
Cash from Investing -10.05
Cash from Financing 33.87
Net change in Cash -0.23
Free Cash Flow -23.43
Particulars MAR 2021 (Values in Cr)
Net Income 0.40
Cash from Operations -2.85
Cash from Investing -4.37
Cash from Financing 8.49
Net change in Cash 1.25
Free Cash Flow -0.06
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 28.97 14.20 1.50 222.01 25.97 / 67.90
BLISS GVS PHARMA LTD 144.15 13.91 1.34 1524.95 105.05 / 190.65
CIPLA LTD 1517.20 22.52 3.72 122555.05 1310.05 / 1672.20
FERMENTA BIOTECH LIMITED 340.35 8.94 2.56 1001.68 219.00 / 449.00
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 28.97 23.55 4.03 222.01 25.97 / 67.90
AMRUTAJAN HEALTH LTD 689.65 35.17 5.82 1993.82 548.05 / 829.00
ASTRAZENECA PHARMA IND LT 9138.35 98.83 28.59 22845.88 6301.00 / 10653.05
BLISS GVS PHARMA LTD 144.15 19.45 1.38 1524.95 105.05 / 190.65

SENORES PHARMACEUTICALS L shareholding pattern

Holding

41.3%
45.79%
4.28%
8.61%
Name Shares Category
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)

Transparent Pricing and 360° Services

Choose a Plan That Suits Your Goals and Needs

greenshadow greenshadow redshadow pricing-pack Freedom Pack
₹20/order 14.99% p.a. MTF
tick Stock Picks by Research Analysts tick Seamless Onboarding

Subscription Charge : FREE

greenshadow greenshadow redshadow pricing-pack

Professional Pack

₹10/order 11.99% p.a. MTF
tick Stock Picks by Research Analysts tick Seamless Onboarding

Subscription Charge : ₹2,500 Yearly

50% Brokerage Savings
greenshadow greenshadow redshadow pricing-pack

Signature

0.2% on Delivery 11.99% p.a. MTF
tick Dedicated Relationship Manager tick Customised Brokerage Support tick Stock Picks by Research Analysts tick Experienced Dealer Support

News

Left Arrow
Right Arrow

SENORES PHARMACEUTICALS L Technicals Summary

  • EMA & SMA
  • Resistance and Support
  • Delivery and Volume
  • Beta
  • Price Change Analysis
816.40 3.85 redarrow
red-green-graph indicator
0 Bearish
16 Bullish
  • 5 Days 775.40
  • 26 Days 778.90
  • 10 Days 778.20
  • 50 Days 763.80
  • 12 Days 779.30
  • 100 Days 724.70
  • 20 Days 780.50
  • 200 Days 652.20
784.70 PIVOT

First Support

769.40

First Resistance

801.40

Second Support

752.70

Second Resistance

816.70

Third Support

737.40

Third Resistance

833.40

RSI

52.00

ADX

12.53

MACD

0.32

Williams % R

-48.44

Commodity Channel Index (CCI)

-17.77

Date

2025-12-12

Week

87901.00

Same Day

123820.00

Month

109406.00

1 Year

1.48

3 Year

1.47

Over 1 Month

1.22%

down

Over 1 Year

41.11%

down

Over 3 Months

13.94%

down

Over 3 Years

0.00%

down

Over 6 Months

43.93%

down

Over 5 Years

0.00%

down

SENORES PHARMACEUTICALS L Corporate Actions

SENORES PHARMACEUTICALS L Share Price

Senores Pharmaceuticals Limited was originally incorporated as 'Senores Pharmaceuticals Private Limited' through a Certificate of Incorporation dated December 26, 2017, issued by the Registrar of Companies, Central Registration Centre. Thereafter, the name of the Company was changed to 'Senores Pharmaceuticals Limited' upon conversion to a Public Limited Company and a fresh Certificate of Incorporation dated September 4, 2023, was issued by the RoC to the Company.

Senores Pharma is a global research driven pharmaceutical company engaged in developing and manufacturing a wide range of pharmaceutical products predominantly for Regulated Markets across various therapeutic areas and dosage forms. The Regulated Markets business is focused on Regulated Markets of US and Canada. The Company has adopted a strategy of identifying, developing and commercializing specialty and complex niche products in the mid-market range and received approvals for 19 ANDAs. Further, it develop and manufacture pharmaceutical products across various therapeutic areas for Emerging Markets, having a presence across 43 countries. The Company operate a Critical Care Injectables Business, supplying critical care injectables to hospitals across India through distributors, and manufacture APIs for the domestic market and SAARC countries.

In 2021, the Company incorporated a wholly owned subsidiary, Senores Pharmaceuticals Inc in the US. It then entered the new segment of API by acquiring Ratnagene Lifescience Private Limited. The Company started domestic business with the launch of the Critical Care Injectables Business in 2022.

The Company further acquired majority stake in Havix Group Inc., making it a subsidiary of the Company in 2023. It consolidated presence in emerging markets by acquiring shares in Ratnatris Pharmaceuticals Private Limited, making it a Subsidiary of the Company in 2023. The Company has launched CMO product in the US with Jubilant Cadista Pharmaceuticals Inc., in 2024.

The Company launched the IPO of 14,887,723 Equity Shares of face value Rs 10 each, by raising money aggregating to Rs 582.11 Crore, comprising a fresh issue of 12,787,723 equity shares amounting to Rs 500 Crore and the offer for sale of 2,100,000 equity shares amounting to Rs 82.11 Cr in December, 2024.

The Company has commenced manufacturing activities at its greenfield API plant located in Gujarat in FY 2025.

Parent organization Indian Private
NSE symbol SENORES
Founded 2017
stock

Trade stocks with ease

Sign-in to trade with your demat account, or set up a new demat account for free

Board Of Directors

Left Arrow
Right Arrow

Similar stocks

Left Arrow
Right Arrow

Frequently Asked Questions

What is the Current Share Price of Senores Pharmaceuticals Ltd?

Answer Field

Senores Pharmaceuticals Ltd share price is for NSE ₹ 813.85 & for BSE ₹ 813.85 as on Dec 16 2025 10:44 AM.

What is the Market Cap of Senores Pharmaceuticals Ltd Share?

Answer Field

The market cap of Senores Pharmaceuticals Ltd for NSE ₹ 3,748.07 & for BSE ₹ 3,748.07 as on Dec 16 2025 10:44 AM.

What is the 52 Week High and Low of Senores Pharmaceuticals Ltd?

Answer Field

The 52 Week High and Low of Senores Pharmaceuticals Ltd for NSE is ₹ 848.50 and ₹ 435.25 and for BSE is ₹ 847.90 and ₹ 440.00.

What is 1 year return for Senores Pharmaceuticals Ltd?

Answer Field

The 1 year returns on the stock has been 41.11%.

What is the P/E Ratio of Senores Pharmaceuticals Ltd Share?

Answer Field

As on Dec 16 2025 10:44 AM the price-to-earnings (PE) ratio for Senores Pharmaceuticals Ltd share is 296.06.

What is the PB ratio of Senores Pharmaceuticals Ltd Share?

Answer Field

As on Dec 16 2025 10:44 AM, the price-to-book (PB) ratio for Senores Pharmaceuticals Ltd share is 155.05.

How to Buy Senores Pharmaceuticals Ltd Share?

Answer Field

You can trade in Senores Pharmaceuticals Ltd shares with Bajaj Broking by opening a demat account.

How to Buy Senores Pharmaceuticals Ltd Share on Bajaj Broking App?

Answer Field

To buy Senores Pharmaceuticals Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “Senores Pharmaceuticals Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

No results found

close-image

Get Free Demat Account*

+91
close-img

Authorise with OTP

Enter the 4-Digit OTP sent to
edit
OTP expires in 00:59